p.117 抽出テキスト

511. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70. PMID: 12482795 512. Lieve KV, van der Werf C, Wilde AA. Catecholaminergic Polymorphic Ventricular Tachycardia. Circ J 2016; 80: 1285-1291. PMID: 27180891 513. Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol 2015; 8: 633-642. PMID: 25713214 514. Leinonen JT, Crotti L, Djupsjöbacka A, et al. The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia? Int J Cardiol 2018; 250: 139-145. PMID: 29032884 515. Kallas D, Roston TM, Franciosi S, et al. Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2021; 18: 1825-1832. PMID: 34333088 516. Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2011; 8: 864-871. PMID: 21315846 517. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74. PMID: 12093772 518. van der Werf C, Nederend I, Hofman N, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol 2012; 5: 748-756. PMID: 22787013 519. Lamba A, Roston TM, Peltenburg PJ, et al. An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2024; 21: 1767-1776. PMID: 38588993 520. Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. JAMA Cardiol 2022; 7: 504-512. PMID: 35353122 521. Shimamoto K, Ohno S, Kato K, et al. Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1. Heart 2022; 108: 840-847. PMID: 35135837 522. Ozawa J, Ohno S, Fujii Y, et al. Differential Diagnosis Between Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome Type 1 - Modified Schwartz Score. Circ J 2018; 82: 2269-2276. PMID: 29925740 523. Tester DJ, Dura M, Carturan E, et al. A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors. Heart Rhythm 2007; 4: 733-739. PMID: 17556193 524. Tester DJ, Wong LCH, Chanana P, et al. Cardiac Genetic Predisposition in Sudden Infant Death Syndrome. J Am Coll Cardiol 2018; 71: 1217-1227. PMID: 29544605 525. Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103: 485-490. PMID: 11157710 526. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196-200. PMID: 11208676 527. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378- 1384. PMID: 11704930 528. Gray B, Bagnall RD, Lam L, et al. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2016; 13: 1652-1660. PMID: 27157848 529. Gao J, Makiyama T, Yamamoto Y, et al. Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circ Arrhythm Electrophysiol 2023; 16: e011387. PMID: 36866681 530. Gomez-Hurtado N, Boczek NJ, Kryshtal DO, et al. Novel CPVT-Associated Calmodulin Mutation in CALM3 (CALM3- A103V) Activates Arrhythmogenic Ca Waves and Sparks. Circ Arrhythm Electrophysiol 2016; 9: e004161. PMID: 27516456 531. Devalla HD, Gélinas R, Aburawi EH, et al. TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. EMBO Mol Med 2016; 8: 1390-1408. PMID: 27861123 532. Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet 2012; 21: 2759-2767. PMID: 22422768 533. Priori SG, Mazzanti A, Santiago DJ, et al. Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5/5. J Am Coll Cardiol 2021; 77: 2592-2612. PMID: 34016269 534. Ohno S, Hasegawa K, Horie M. Gender Differences in the Inheritance Mode of RYR2 Mutations in Catecholaminergic Polymorphic Ventricular Tachycardia Patients. PLoS One 2015; 10: e0131517. PMID: 26114861 535. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009; 54: 2065-2074. PMID: 19926015 536. Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J 2022; 43: 1500-1510. PMID: 34557911 537. Shimamoto K, Sumitomo N, Nabeshima T, et al. Novel Compound Heterozygous Variants in Trans-2,3-Enoyl-Coenzyme A Reductase-Like Gene Associated With Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Case Rep 2024; 29: 102364. PMID: 38756419 538. Kawamura M, Ohno S, Naiki N, et al. Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan. Circ J 2013; 77: 1705-1713. PMID: 23595086 539. Miyata K, Ohno S, Itoh H, et al. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations. Intern Med 2018; 57: 1813-1817. PMID: 29434162 540. Sumitomo N, Sakurada H, Taniguchi K, et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 2007; 71: 1606-1609. PMID: 17895559 541. Lieve KVV, Verhagen JMA, Wei J, et al. Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2019; 16: 220-228. PMID: 30170228 542. Aizawa Y, Komura S, Okada S, et al. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). Int Heart J 2006; 47: 381-389. PMID: 16823244 543. Dochi K, Watanabe H, Kawamura M, et al. Flecainide reduces ventricular arrhythmias via a mechanism that differs from that of β-blockers in catecholaminergic polymorphic ventricular tachycardia. J Arrhythm 2013; 29: 255-260. 544. Inoue YY, Aiba T, Kawata H, et al. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. Europace 2018; 20: 1675-1682. PMID: 29309601 545. Giudicessi JR, Ackerman MJ. Exercise testing oversights underlie missed and delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia in young sudden cardiac arrest survivors. Heart Rhythm 2019; 16: 1232-1239. PMID: 30763784 546. Roston TM, Kallas D, Davies B, et al. Burst Exercise Testing Can Unmask Arrhythmias in Patients With Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Clin Electrophysiol 2021; 7: 437-441. PMID: 33888264 547. Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2012; 23: 194-199. PMID: 21954897 548. Fujita S, Nishida K, Irabu H, et al. Catecholaminergic polymorphic ventricular tachycardia managed as orthostatic dysregulation and epilepsy in 11- and 15-year-old sisters. Pediatr Int 2018; 60: 998-1001. PMID: 30157307 549. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075. PMID: 12968091 550. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119: 2426-2434. PMID: 19398665 551. Roston TM, Yuchi Z, Kannankeril PJ, et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.